Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.99K Buy
35
+15
+75% +$874 ﹤0.01% 3008
2026
Q2
$1.16K Hold
20
– – ﹤0.01% 3117
2026
Q1
$1.16K Buy
20
+8
+67% +$434 ﹤0.01% 2716
2025
Q4
$554 Sell
12
-34
-74% -$1.52K ﹤0.01% 2911
2025
Q3
$1.66K Sell
46
-12
-21% -$398 ﹤0.01% 2526
2025
Q2
$1.88K Buy
58
+20
+53% +$656 ﹤0.01% 2322
2025
Q1
$1.44K Buy
38
+34
+850% +$2.72K ﹤0.01% 2377
2024
Q4
$327 Hold
4
– – ﹤0.01% 2502
2024
Q3
$457 Buy
+4
New +$360 ﹤0.01% 2481

Other funds holding PCVX

BFC Planning's PCVX Position: Q3 2026 in Review

BFC Planning increased its Vaxcyte (PCVX) stake by 75% in Q3 2026, buying an estimated $874 and bringing the position to 35 shares worth $1.99K. The position accounts for ﹤0.01% of the portfolio, ranked #3008.

BFC Planning first reported a position in PCVX in Q3 2024 and has held it in 9 quarters since. 259 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • BFC Planning held 35 shares of Vaxcyte worth $1.99K as of Q3 2026.
  • BFC Planning bought 15 Vaxcyte shares in Q3 2026, an estimated $874.
  • Vaxcyte made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3008 holding.
  • BFC Planning first reported a position in Vaxcyte in Q3 2024 and has held it in 9 quarters since.
  • 259 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.